On March 20, 2026, Swiss pharmaceutical giant Roche officially announced the discontinuation of emugrobart, an experimental antibody aimed at treating spinal muscular atrophy (SMA) and facioscapulohumeral muscular dystrophy (FSHD). The decision followed clinical data indicating the drug failed to deliver the expected muscle-building benefits.
Key details of the announcement:
-
Reason for termination: Following a comprehensive assessment of the trial’s first part, Roche determined that emugrobart “did not consistently deliver” sufficient improvements in muscle growth and motor function. Despite its mechanism of targeting myostatin to prevent muscle fiber breakdown, the biological impact was insufficient to warrant further study.
-
Impact on the patient community: Roche issued letters to patient advocacy groups in Europe expressing regret over the news. However, the company emphasized its continued commitment to its approved oral therapy, Evrysdi, which remains a blockbuster treatment in the SMA market.
-
Shifting market landscape: Roche’s exit is seen as a major win for competitors. Analysts suggest that Scholar Rock, with its candidate apitegromab, now stands as the potential lone leader in muscle-building therapy for SMA, with an FDA approval expected later this year.
-
Scientific contribution: Roche plans to share the gathered trial data at upcoming medical conferences to help inform the development of future treatments within the scientific community.
This setback highlights the immense difficulty of developing therapies that target muscle-inhibiting proteins and reshapes the competitive landscape for rare neuromuscular diseases.